Cargando…

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report

Thirty two year old Caucasian female presented 2 months post partum with fevers, cough and shortness of breath. CT scan of the chest to rule out pulmonary embolism revealed mediastinal lymphadenopathy. Biopsy of the nodes revealed classic Hodgkin's lymphoma and she received ABVD chemotherapy. S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subbiah, Vivek, Ly, Uyen K, Khiyami, Amer, O'Brien, Timothy
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211302/ https://www.ncbi.nlm.nih.gov/pubmed/18036249 http://dx.doi.org/10.1186/1752-1947-1-148

Ejemplares similares

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
por: Gangopadhyay, Aparna, et al.
Publicado: (2012)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
por: Bond, David A., et al.
Publicado: (2019)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
por: Cotteret, Camille, et al.
Publicado: (2020)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
por: DeBoer, Rebecca J., et al.
Publicado: (2020)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
por: Yonezawa, Ryo, et al.
Publicado: (2023)

A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD
por: Chakraborty, Rajshekhar, et al.
Publicado: (2015)

Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
por: Makiyama, Junya, et al.
Publicado: (2020)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
por: Honoré, Bent, et al.
Publicado: (2022)

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease
por: Ciccarone, Mariavita, et al.
Publicado: (2023)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
por: André, Marc P. E., et al.
Publicado: (2020)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
por: Suwanban, Tawatchai, et al.
Publicado: (2023)

P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
por: Pavlovsky, A., et al.
Publicado: (2022)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz, Carminia, et al.
Publicado: (2018)

The Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy
por: Brusamolino, Ercole, et al.
Publicado: (2012)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
por: Dickinson, Michael, et al.
Publicado: (2023)

A Difficult Case of Hodgkin Lymphoma with Differential Diagnosis of Tuberculosis and Sarcoidosis
por: Göknar, Nilüfer, et al.
Publicado: (2015)

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
por: Santisteban-Espejo, Antonio, et al.
Publicado: (2022)

P1082: SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA
por: Fiad, N. L., et al.
Publicado: (2022)

Sarcoid Reactions after Chemotherapy for Hodgkin’s Lymphoma
por: Wirk, Baldeep
Publicado: (2010)

Late-onset sarcoidosis in a patient with gastric mucosa-associated lymphoid tissue non-Hodgkin lymphoma: A case report
por: TORCHIO, MARTINA, et al.
Publicado: (2014)

Sustained remission after ABVD treatment for interdigitating dendritic cell sarcoma
por: Helbig, Grzegorz, et al.
Publicado: (2014)

A novel immunomodulatory and molecularly targeted strategy for refractory Hodgkin's lymphoma
por: Subbiah, Vivek, et al.
Publicado: (2013)

Management of Non-Hodgkin's Lymphoma in Maxillofacial Region with Chemotherapy
por: Moin, Ayesha, et al.
Publicado: (2017)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_boqqto3hdq6253oj9co6fdvs83